Baseline characteristics for INFRONT 3: A Phase 3 double blind, placebo[...]
Notification Letter and Reply Form to Non registered Shareholders[...]
05/11/2023 | Press release | Distributed by Public on 05/11/2023 15:49
Please select the service you want to use:
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact